BSE filing, NSE: EMKAY. Summary written from the filing by ALFA Finder's alert engine.
Emkay Global Financial Services Ltd: key numbers
- Share price
- ₹287.40
- Market cap
- ₹802.9 Cr
- Revenue (annual)
- ₹349.0 Cr
- Net profit (annual)
- ₹11.90 Cr
- P/E (TTM)
- 16.9×Sector 19.7×
- Promoter holding
- 72.89%+0.06% QoQ
- FII holding
- 0.88%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Emkay Global Financial Services Ltd
All →Emkay Global Financial Services Capital Structure Change
Emkay Global will invest ₹30.00 Crore in cash in wholly owned subsidiary Emkay Capital. The related-party deal completes within 90 days.
- Value
- ₹30.00 Cr
- Execution
- Within 90 days
Emkay Global Financial Services Acquisition Worth ₹30 Cr
Emkay Global will buy Emkay Capital Private Limited for Rs 30 Crore in cash. The related-party deal is expected to complete within 90 days.
- Value
- ₹30.00 Cr
Emkay Global Financial Services Merger & Restructuring Worth ₹2.75 Cr
Emkay Global agreed to sell its Wealth Management Business to a step-down subsidiary, Emkay Wealth Advisory, for Rs. 2.75 Crore cash. Completion is expected by 26 January 2027.
- Value
- ₹2.75 Cr
- Execution
- Completion expected by 26 January 2027
Emkay Global Financial Services Acquisition Worth ₹2.05 Cr
Emkay Capital, a subsidiary of Emkay Global, agreed to acquire Emkay Wealth Advisory for Rs. 2.05 Crore cash. The deal is an intra-group restructuring, and the target is a SEBI-registered investment adviser.
- Value
- ₹2.05 Cr
- Execution
- 90 days
Emkay Global Financial Services Acquisition Worth ₹21.38 Cr
Emkay Capital, a subsidiary, will acquire Emkay Investment Managers for Rs.21.38 Crore cash. The related-party deal is at arm's length and payable in tranches.
- Value
- ₹21.38 Cr
- Execution
- 90 days
Emkay Global Financial Services Merger & Restructuring Worth ₹30 Cr
Emkay Global approved transferring two subsidiaries to new subsidiary ECPL and slump-selling its wealth business. Up to Rs.30 Crore rights investment in ECPL was also approved.
- Value
- ₹30.00 Cr
- Execution
- Divestment completion expected within 90 days of SPA execution, subject to regulatory approvals
Other employee stock options announcements
All →RateGain Travel Technologies Employee Stock Options
RateGain granted 53,021 Stock Appreciation Rights under its SAR Scheme 2022 at ₹800 and ₹862.25 per unit. The grants vest over four years and are exercisable within three years of vesting.
- Execution
- Vesting over 4 years (10% Y1, 20% Y2, 30% Y3, 40% Y4); exercisable within 3 years of vesting
Aye Finance Employee Stock Options
Aye Finance's employee welfare trust transferred 89,501 equity shares to grantees on exercising ESOP options. The share capital remains unchanged, so no new issuance occurs.
Aarti Pharmalabs Employee Stock Options
Aarti Pharmalabs granted 850 stock options to employees under its PSOP 2023 at Rs.5 exercise price. This is an employee incentive grant, not a capital raise.
OnEMI Technology Solutions Employee Stock Options
OnEMI Technology allotted 69,000 equity shares on exercise of employee stock options under the Kissht ESOP 2022 plan. The shares rank pari passu with existing equity.
Bliss GVS Pharma Employee Stock Options
Bliss GVS Pharma seeks shareholder approval via postal ballot for new employee stock option plans 2026. Up to 26,50,000 options are proposed; voting closes November 27, 2026.
Bandhan Bank Employee Stock Options
Bandhan Bank's board granted 32,98,871 stock options under ESOP Series 1 (Tranche 9) at Rs 151.91 per option. The options vest over four years, with each option convertible into one equity share.